Avior Wealth Management LLC Buys 309 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Avior Wealth Management LLC raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,858 shares of the medical equipment provider’s stock after purchasing an additional 309 shares during the period. Avior Wealth Management LLC’s holdings in Lantheus were worth $363,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Macquarie Group Ltd. raised its stake in shares of Lantheus by 21.7% in the 1st quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 108 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 156 shares in the last quarter. RFG Advisory LLC increased its position in shares of Lantheus by 4.4% during the 3rd quarter. RFG Advisory LLC now owns 3,940 shares of the medical equipment provider’s stock worth $274,000 after purchasing an additional 167 shares in the last quarter. Prosperity Financial Group Inc. increased its position in shares of Lantheus by 6.2% during the 3rd quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 173 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Lantheus by 3.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock worth $432,000 after purchasing an additional 188 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Insider Activity

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Lantheus stock in a transaction dated Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 94,545 shares of company stock valued at $6,169,936. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LNTH. JMP Securities reiterated a “market outperform” rating and set a $100.00 target price on shares of Lantheus in a research report on Friday, February 23rd. Truist Financial reiterated a “buy” rating and set a $82.00 target price (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Finally, B. Riley increased their target price on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.71.

Lantheus Trading Up 2.4 %

LNTH opened at $63.81 on Friday. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $4.37 billion, a PE ratio of 13.75 and a beta of 0.53. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $100.85. The firm has a 50-day moving average price of $60.81 and a two-hundred day moving average price of $62.97.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.